Lineage Cell Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Lineage Cell Therapeutics, Inc. (LCTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 2.00% for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2016-03-15
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2015 was 2.00%, a 33.33% decline from fiscal 2014.
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2014 was 3.00%.
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2013 was 0.00%.
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2012 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2015-12-31 | 2.00% 10-K · filed 2016-03-15 |
| 2014-12-31 | 3.00% 10-K · filed 2016-03-15 |
| 2013-12-31 | 0.00% 10-K · filed 2016-03-15 |
| 2012-12-31 | 0.00% 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |